Related Experiment Video
Updated: Jun 16, 2025
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
Published on: April 12, 2019
Gambogic acid suppresses osteosarcoma progression through upregulation of FOXO3a
Yawei Hu1,2, Jiawen Wu2, Songqing Ye3
1Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China.
Background:
Osteosarcoma is a prevalent bone cancer in children and adolescents, posing significant treatment challenges due to its high metastatic potential and resistance to traditional chemotherapy. Gambogic Acid (GA), a natural compound, has demonstrated promising anticancer properties, including inhibition of cell proliferation and induction of apoptosis.
Methods:
This study evaluated the anticancer effects of GA on osteosarcoma cell lines 143B and U2OS through cell viability assays, proliferation tests, wound healing assays, and flow cytometry to assess migration and apoptosis. RNA sequencing and RT-qPCR analyses were conducted to identify molecular mechanisms, with a focus on the tumor suppressor transcription factor FOXO3a. siRNA-mediated knockdown of FOXO3a was performed to determine its role in GA's mechanism of action.
Results:
GA treatment significantly reduced cell viability and proliferation in a dose- and time-dependent manner, as shown by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and CCK-8 assays. Wound healing assays revealed a marked inhibition of cell migration, while flow cytometry confirmed a significant increase in apoptosis rates following GA treatment. RNA sequencing identified FOXO3a as a key upregulated gene in both cell lines after GA exposure, which was validated by RT-qPCR. Importantly, FOXO3a knockdown diminished GA's effects on cell viability, migration, and apoptosis, underscoring its pivotal role in mediating GA's anticancer activity.
Conclusions:
The findings suggest that GA exerts potent anticancer effects on osteosarcoma cells through the upregulation of FOXO3a, a critical tumor suppressor. These results provide a foundation for further exploration of GA as a novel therapeutic agent for osteosarcoma, potentially offering a safer alternative to conventional chemotherapy. Future research will aim to elucidate the detailed mechanisms underlying the interaction between GA and FOXO3a and to optimize GA-based therapeutic strategies.
Insights
Gambogic Acid (GA) effectively inhibits osteosarcoma growth and migration by increasing the tumor suppressor FOXO3a. This natural compound shows potential as a novel cancer therapy, offering an alternative to traditional chemotherapy.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Osteosarcoma is a challenging bone cancer in children and adolescents, often resistant to chemotherapy.
- Gambogic Acid (GA), a natural compound, exhibits anticancer properties, including inhibiting proliferation and inducing apoptosis.
Purpose of the Study:
- To evaluate the anticancer effects of Gambogic Acid (GA) on osteosarcoma cell lines.
- To investigate the molecular mechanisms underlying GA's action, focusing on the role of FOXO3a.
Main Methods:
- Cell viability, proliferation, migration (wound healing), and apoptosis assays were performed on osteosarcoma cells treated with GA.
- RNA sequencing and RT-qPCR identified FOXO3a as a key target.
- FOXO3a knockdown was used to confirm its role in GA's mechanism.
Main Results:
- GA significantly reduced osteosarcoma cell viability, proliferation, and migration in a dose- and time-dependent manner.
- GA treatment increased apoptosis rates and upregulated FOXO3a expression.
- Knockdown of FOXO3a attenuated the anticancer effects of GA, confirming its essential role.
Conclusions:
- Gambogic Acid demonstrates potent anticancer activity against osteosarcoma cells by upregulating the tumor suppressor FOXO3a.
- GA represents a promising therapeutic candidate for osteosarcoma, potentially offering a safer alternative to conventional treatments.
- Further research is warranted to explore GA's detailed mechanisms and optimize its therapeutic application.
